Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Starbucks is ditching legacy software vendors for homegrown AI tools. Here's why that could eventually benefit companies like Toast.
Itʻs been four years since Netflix stock has been this cheap.
Jim Cramer keeps pounding the table on one chip stock even as rivals flood the AI market with competing silicon. The reason he gives sounds almost too simple, but the financials suggest he has a point.
Lawmakers are buying and selling stocks in the exact industries they regulate, and nothing about it breaks the law. Here is what the latest filings reveal about where congressional money is moving before the votes happen.
Homes continue to become less affordable, which is bad news for builders.
Both Meta and NVIDIA delivered blowout quarters on the same AI wave, yet investors treated the two stocks very differently this summer. One company quietly flipped its biggest cost line into a potential revenue stream, and that changes the comparison entirely.
Jensen Huang has been placing bold bets on optical connectivity firms that could define the next chokepoint of the AI race, and a recent market pullback may have just handed investors a rare entry point into his favorite picks.
CrowdStrike's stock has been strong, helped by accelerating ARR growth and a stock split.
Tesla just posted its strongest earnings inflection in years, yet the stock sits at a valuation that prices in a future most investors have never seen before. The real question is whether that future arrives on schedule or falls apart in Q2.
Tech giants are borrowing at a pace that would have seemed unthinkable just a few years ago, betting that AI revenues will eventually justify the load. But skeptical investors, blocked construction projects, and corporate silence about real returns are raising questions the industry does not yet have answers for.
Chasing high yields in mid-2026 is easy. Finding dividends that businesses can actually sustain is the harder problem, and these five names across REITs, midstream, and fintech clear that bar while still offering yields near 5%.
While the Nasdaq bleeds and investors pile into healthcare and staples at record highs, one Wall Street strategist is shopping the wreckage in memory chips, and her valuation case is harder to dismiss than it looks.
SK Hynix (SKHYV, SKHY) made its impressive Nasdaq (^IXIC) debut on Friday, but the South Korean shares (000660.KS) are now plunging. Yahoo Finance Senior Business Reporter Ines Ferré and AInvest managing editor Adam Shapiro chat with Morning Brief host Julie Hyman about the company's market moves and earnings outlook.
The company's operational improvements make it a compelling stock for many portfolios.
It isn't just investors who are bullish about SpaceX; some analysts also have rosy outlooks for the business.
Coke's strong results back up its premium valuation, but Pepsi may simply be too cheap to ignore.
Can the streaming expert bounce back?
The chipmaker says demand remains strong as new AI products stay on schedule.
Michael Burry built his reputation betting against the crowd at exactly the right moment, and his latest wager targets a beaten-down sector most investors have already written off. The question is whether his contrarian logic holds up where others have already lost their shirts.
The electric vehicle company will post its second-quarter results next week.
A groundbreaking ceremony marked the start of Phase II at the Chiayi Science Park, which is expected to produce $9.35 billion in annual output
Nvidia still dominates AI training, but a quiet shift in how hyperscalers spend their next trillion dollars is opening a lane for two chip designers most investors have barely considered.
Texas Pacific surged on rising oil and gas prices and increasing AI infrastructure development in West Texas.
Here is a way to collect an upfront income stream from one of the market's hottest stocks, which you keep no matter what, while lining up a chance to buy it at a serious discount if it ever pulls back.
Johnson & Johnson (NYSE:JNJ) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate. The stock has already told you what it thinks of the fundamentals, rising nearly 25% year to date and nearly 66% over the past year. Yet the ... The Real Case for Buying Johnson & Johnson (JNJ) Before July 15
Broadcom and NVIDIA both crushed their latest earnings, but the gap between them is widening in ways the headline numbers hide. One company carries a timing advantage, a marquee customer anchor, and an AI growth rate that puts its rival on defense through year-end.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
